Hurst-Hess_2023_Antimicrob.Agents.Chemother_67_e0016223

Reference

Title : Intrapulmonary Treatment with Mycobacteriophage LysB Rapidly Reduces Mycobacterium abscessus Burden - Hurst-Hess_2023_Antimicrob.Agents.Chemother_67_e0016223
Author(s) : Hurst-Hess K , Walz A , Yang Y , McGuirk H , Gonzalez-Juarrero M , Hatfull GF , Ghosh P , Ojha AK
Ref : Antimicrobial Agents & Chemotherapy , 67 :e0016223 , 2023
Abstract :

Intrinsic and acquired antibiotic resistance in Mycobacterium abscessus presents challenges in infection control, and new therapeutic strategies are needed. Bacteriophage therapy shows promise, but variabilities in M. abscessus phage susceptibility limits its broader utility. We show here that a mycobacteriophage-encoded lysin B (LysB) efficiently and rapidly kills both smooth- and rough-colony morphotype M. abscessus strains and reduces the pulmonary bacterial load in mice. LysB aerosolization presents a plausible treatment for pulmonary M. abscessus infections.

PubMedSearch : Hurst-Hess_2023_Antimicrob.Agents.Chemother_67_e0016223
PubMedID: 37154689

Related information

Family Lysin_B_C_ter

Citations formats

Hurst-Hess K, Walz A, Yang Y, McGuirk H, Gonzalez-Juarrero M, Hatfull GF, Ghosh P, Ojha AK (2023)
Intrapulmonary Treatment with Mycobacteriophage LysB Rapidly Reduces Mycobacterium abscessus Burden
Antimicrobial Agents & Chemotherapy 67 :e0016223

Hurst-Hess K, Walz A, Yang Y, McGuirk H, Gonzalez-Juarrero M, Hatfull GF, Ghosh P, Ojha AK (2023)
Antimicrobial Agents & Chemotherapy 67 :e0016223